8 Regadenoson and QTC prolongation: a prospective study
8 Regadenoson and QTC prolongation: a prospective study
About this item
Full title
Publisher
London: BMJ Publishing Group Ltd and British Cardiovascular Society
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd and British Cardiovascular Society
Subjects
More information
Scope and Contents
Contents
IntroductionRegadenoson is a highly selective adenosine A2 receptor blocker. It induces profound coronary vasodilation, without significant atrioventricular block or bronchoconstriction, enabling sustained uptake of radioisotopes for up to 30 minutes to enable myocardial perfusion imaging (MPI). However, its effect on the QTc interval remains uncer...
Alternative Titles
Full title
8 Regadenoson and QTC prolongation: a prospective study
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2724343510
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2724343510
Other Identifiers
ISSN
1355-6037
E-ISSN
1468-201X
DOI
10.1136/heartjnl-2022-ICS.8
